68Ga-PSMA PET in prostate cancer: a systematic review and meta-analysis of the observer agreement

PET as a Translational Tool in Drug Development for Neuroscience Compounds

“…The quantitative properties of PET and the ability to assess biological functions are also applied in other therapeutic areas. For instance, whole‐body hybrid PET imaging combined with computed tomography and/or magnetic resonance is used for the diagnosis and staging of solid tumors, and the development of new radioligands for specific targets (e.g., [ 68 Ge]DOTATOC or [ 68 Ge]DOTATATE for neuroendocrine tumors or [ 68 Ge]PSMA for prostate cancer) has enabled the evaluation of tumors that would be otherwise difficult to access 1–3 …”

“…For instance, whole-body hybrid PET imaging combined with computed tomography and/or magnetic resonance is used for the diagnosis and staging of solid tumors, and the development of new radioligands for specific targets (e.g., [ 68 Ge]DOTATOC or [ 68 Ge]DOTATATE for neuroendocrine tumors or [ 68 Ge]PSMA for prostate cancer) has enabled the evaluation of tumors that would be otherwise difficult to access. [1][2][3] The importance of PET in CNS drug development was highlighted by Morgan et al, 4 where the term "three pillars of survival" was coined based on a systematic evaluation of phase II failures, uncovering that in almost 50% of the drug development programs investigated it was not possible to conclude whether the drug mechanism had been tested adequately due to unknown target site, drug exposure or target occupancy. 4 The three pillars have undoubtedly been implemented in many pharma companies.…”

Exploration of 68Ga-DOTA-MAL as a Versatile Vehicle for Facile Labeling of a Variety of Thiol-Containing Bioactive Molecules

“…Other positron nuclides already applied in clinical trials include 11 C, 89 Zr, and 124 I; however, each of these also has its own disadvantages that prevent further application, such as the short half-life of 11 C, the osteophilic property of 89 Zr, and instability of 124 I-labeled probes. ,− Moreover, the production of all the above nuclides requires an expensive on-site cyclotron, which undoubtedly further limits their applications. Recently, inspired by the successful clinical use of 68 Ga-labeled bioactive molecules such as 68 Ga-DOTA-TATE, 68 Ga-FAPI, and 68 Ga-PSMA, 68 Ga-labeled diagnostic tracers have become a hotspot in the design of biomedical imaging probes. − Compared to other clinically available short-lived positron emitters ( 11 C and 18 F), 68 Ga exhibits some unique characteristics that make it attractive, including suitable nuclear decay properties for PET imaging (β + 0.74 MeV, 89% abundance, t 1/2 = 67.7 min), generator production, commercially available chelators, and the potential to form a theranostic pair with 177 Lu/ 90 Y. , …”

“…Recently, inspired by the successful clinical use of 68 Ga-labeled bioactive molecules such as 68 Ga-DOTA-TATE, 68 Ga-FAPI, and 68 Ga-PSMA, 68 Ga-labeled diagnostic tracers have become a hotspot in the design of biomedical imaging probes. 14 − 16 Compared to other clinically available short-lived positron emitters ( 11 C and 18 F), 68 Ga exhibits some unique characteristics that make it attractive, including suitable nuclear decay properties for PET imaging (β + 0.74 MeV, 89% abundance, t 1/2 = 67.7 min), generator production, commercially available chelators, and the potential to form a theranostic pair with 177 Lu/ 90 Y. 11 , 17 …”

177Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With 177Lu-PSMA-I&T

“…Previously, he had undergone androgen deprivation therapy including LHRH agonists (buserelin) and novel androgen axis drugs (enzalutamide) as well as taxane-based chemotherapy (docetaxel and cabazitaxel). PET/CT using 68 Ga-PSMA-I&T 1 , 2 revealed local recurrence as well as multiple (pelvic, retroperitoneal, supraclavicular) lymph node and bone (eg, left femur, arrows) metastases ( A ). Subsequently, PSMA-directed radioligand therapy was recommended according to recent practice 3 , 4 and the decision of the institutional interdisciplinary tumor conference.…”